- Posted Wednesday November 18, 2009
Alliance with France's Institut Paoli-Calmettes focuses on
SCOTTSDALE, Ariz. -- Nov. 18, 2009 -- TGen Drug Development (TD2) and the Institut Paoli-Calmettes (IPC) have forged a strategic alliance that will enable both to maximize their worldwide contributions in the treatment of cancer patients.
The partnership between TD2, a Scottsdale subsidiary of the Phoenix-based Translational Genomics Research Institute (TGen), and Marseille, France-based IPC's comprehensive cancer center will enable both non-profit institutes to speed research discoveries to patients with cancer.
Both organizations will expand their clinical research network to evaluate new therapies in the U.S. and Europe in an effort to more quickly introduce new drugs into clinical trials.
Teams from both TD2 and IPC will focus their efforts on discovering molecular alterations within cancers and finding biomarkers that will help identify new therapeutic targets that can be used to tailor treatments for individual patients.
IPC and TD2 will collaborate on a number of primary tumor and metastasis in selected cancers, as well as initiate an exchange program for medical oncologists between the two institutions.
"Aligning with IPC represents a significant opportunity for TD2 and TGen to further expand our research affiliations into Europe," said Dr. Daniel Von Hoff, TGen's Physician-In-Chief. "In addition to our ongoing collaborations with Luxembourg, this new alliance with IPC will further our goals across both Europe and the United States of providing better treatments in a more timely fashion to our many patients who suffer from a variety of cancer types."
Professor Patrice Viens, a medical oncologist and General Director of IPC, said the alliance with TD2 will enable IPC to bridge new international relationships: "This alliance with TD2 translates to our continuing efforts to expand our collaborations in basic research and medical activities beyond Europe."
IPC is one of the largest university-affiliated comprehensive cancer centers in France, involved in the management of nearly 6,000 new cases of cancer each year. IPC established a Biological Resource Center (BRC) in oncology that has 70,000 tumor and biological fluid samples, mostly of breast, pancreatic and blood cancers. ICP had more than 600 patients in clinical trials during 2008.
IPC is affiliated with the Ovarian Cancer Diagnosis Initiative (OVCAD), which is dedicated to ovarian cancer research, and with the European Consortium for Anticancer Antibody Development (EUCAAD), a European consortium dedicated to anti-angiogenic treatments. It also is involved in collaborations with biotech and pharmaceutical companies.
IPC will join TGen's Pancreatic Cancer Research Team (PCRT), which includes other U.S. and international researchers.
"Our meetings at TGen have confirmed our decision to team up with this premier organization on the cutting edge of research and pharmacogenomics in oncology," Professor Viens said. "In addition we are thrilled to work again with Dr. Von Hoff." Professor Viens and Dr. Von Hoff once worked together at the University of Texas Health Science Center in San Antonio, Texas.
About Institut Paoli-Calmettes
Institut Paoli-Calmettes (IPC) is a comprehensive cancer center in Marseille, France. IPC is part of a network of 20 cancer treatment centers in France. Its priorities are the treatment of cancer patients, education and prevention, as well as basic, translational and clinical research. IPC works to coordinate research among laboratories, biotechnology companies and hospitals. It prides itself on a humanistic mission, keeping the patient at the heart of decisions about treatments, and using the latest innovations and technology. Its more than 1,200-member staff, including more than 160 scientists, annually treats more than 20,000 patients. IPC's research department is affiliated with the Institut National de la Santé et de la Recherche Médicale (INSERM, France's National Institution of Health and Medical Research) and Université de la Méditerranée. For more information, please visit: www.institutpaolicalmettes.fr.
About TGen Drug Development (TD2)
TD2, a wholly owned subsidiary of the Translational Genomics Research Institute (TGen), is a 501(c)3 non-profit organization. TD2 provides innovative services for oncology-focused biopharmaceutical companies using a dedicated team of professionals with broad experience and understanding in drug development. TD2 is uniquely positioned to support the need for improved and accelerated development of new chemical entities (NCE's) for life-threatening diseases. TD2 uses a unique combination of experience gained through its contract research organization business, and an integrated suite of proprietary and non-proprietary tools, preclinical study execution, regulatory affairs assistance, clinical trial design and management, and drug development experts to successfully move therapeutics towards regulatory approval. TD2 is dedicated to reducing the risks and uncertainty inherent in the drug development process. For more information, please visit: www.td2.org.
The Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life changing results. Research at TGen is focused on helping patients with diseases such as cancer, neurological disorders and diabetes. TGen is on the cutting edge of translational research where investigators are able to unravel the genetic components of common and complex diseases. Working with collaborators in the scientific and medical communities, TGen believes it can make a substantial contribution to the efficiency and effectiveness of the translational process. TGen is affiliated with the Van Andel Research Institute in Grand Rapids, Michigan. For more information, please visit: www.tgen.org.
TGen Senior Science Writer